Issues with galactomannan testing
نویسندگان
چکیده
منابع مشابه
Earlier Diagnosis of Invasive Fusariosis with Aspergillus Serum Galactomannan Testing
Cross-reactivity of Fusarium species with serum galactomannan antigen (GMI) test has been observed. We sought to evaluate if GMI could help to early diagnose invasive fusariosis and to monitor treatment response. We reviewed the records of all patients with invasive fusariosis between 2008 and 2012 in three Brazilian hospitals. We selected patients who had at least 1 GMI test within 2 days befo...
متن کاملGalactomannan testing for early diagnosis of Exserohilum rostratum infection.
Exserohilum rostratum is the most common pathogen in the current U.S. outbreak of fungal central nervous system infection, septic arthritis, and localized spinal or paraspinal infections (1). Rapid laboratory diagnosis is urgently needed but is unfortunately still limited. Only 30% of the 372 case patient specimens sent to the Centers for Disease Control and Prevention (CDC) had PCR evidence su...
متن کاملEditorial Commentary: Galactomannan Testing During Mold-Active Prophylaxis
Choosing a prophylactic approach is a strategic decision impacting the choice, timing, and even the indication of in vitro diagnostic tests and antifungal treatments. In the past, clinical studies informing clinical decisions were conducted in settings without prophylaxis. One may object, that empiric antifungal treatment trials allowed enrolling patients on antifungal prophylaxis with fluconaz...
متن کاملDiagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid.
Testing cerebrospinal fluid (CSF) for the presence of galactomannan (GM) antigen may help in diagnosing cerebral aspergillosis (CA). However, the use of the CSF GM test as a diagnostic test has been little studied. We evaluated its diagnostic performance by comparing the CSF GM optical density indexes (ODI) at different cutoffs in patients with probable and proven CA to those in patients withou...
متن کاملScreening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis.
TO THE EDITOR—We read with interest the article by Fisher and colleagues about use of the galactomannan index (GMI) in hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) [1]. The authors reported that the serum GM level at the time of IA diagnosis was significantly associated with the risk of overall and respiratory mortality. In their cohort, GM testing was p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Mycology
سال: 2006
ISSN: 1369-3786,1460-2709
DOI: 10.1080/13693780600904918